{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:47:37Z","timestamp":1793533657858,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ichthyosis covers a wide spectrum of diseases affecting the cornification of the skin. In recent years, new advances in understanding the pathophysiology of ichthyosis have been made. This knowledge, combined with constant development of pathogenesis-based therapies, such as protein replacement therapy and gene therapy, are rather promising for patients with inherited skin diseases. Several ongoing trials are investigating the potency of these new approaches and various studies have already been published. Furthermore, a lot of case series report that biological therapeutics are effective treatment options, mainly for Netherton syndrome and autosomal recessive congenital ichthyosis. It is expected that some of these new therapies will prove their efficacy and will be incorporated in the treatment of ichthyosis.<\/jats:p>","DOI":"10.1186\/s13023-022-02430-6","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T13:08:01Z","timestamp":1657890481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["New developments in the molecular treatment of ichthyosis: review of the literature"],"prefix":"10.1186","volume":"17","author":[{"given":"M. D. W.","family":"Joosten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M. K.","family":"Clabbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jonca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mazereeuw-Hautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-2914","authenticated-orcid":false,"given":"A. H.","family":"Gosty\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"issue":"4","key":"2430_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2009.11.020","volume":"63","author":"V Oji","year":"2010","unstructured":"Oji V, Tadini G, Akiyama M, Blanchet Bardon C, Bodemer C, Bourrat E, et al. Revised nomenclature and classification of inherited ichthyoses: results of the first ichthyosis consensus conference in soreze 2009. J Am Acad Dermatol. 2010;63(4):607\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2430_CR2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaad.2020.01.052","volume":"83","author":"Q Sun","year":"2020","unstructured":"Sun Q, Ren I, Zaki T, Maciejewski K, Choate K. Ichthyosis affects mental health in adults and children: a cross-sectional study. J Am Acad Dermatol. 2020;83(3):951\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2430_CR3","first-page":"E374","volume":"61","author":"G Troiano","year":"2020","unstructured":"Troiano G, Lazzeri G. A review of quality of life of patients suffering from ichthyosis. J Prev Med Hyg. 2020;61(3):E374\u20138.","journal-title":"J Prev Med Hyg"},{"issue":"3","key":"2430_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10701.x","volume":"166","author":"J Mazereeuw-Hautier","year":"2012","unstructured":"Mazereeuw-Hautier J, Dreyfus I, Barbarot S, Serrentino L, Bourdon-Lanoy E, Ezzedine K, et al. Factors influencing quality of life in patients with inherited ichthyosis: a qualitative study in adults using focus groups. Br J Dermatol. 2012;166(3):646\u20138.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2430_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/bjd.17203","volume":"180","author":"J Mazereeuw-Hautier","year":"2019","unstructured":"Mazereeuw-Hautier J, Vahlquist A, Traupe H, Bygum A, Amaro C, Aldwin M, et al. Management of congenital ichthyoses: European guidelines of care, part one. Br J Dermatol. 2019;180(2):272\u201381.","journal-title":"Br J Dermatol"},{"issue":"6","key":"2430_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/11311070-000000000-00000","volume":"10","author":"V Oji","year":"2009","unstructured":"Oji V, Traupe H. Ichthyosis: clinical manifestations and practical treatment options. Am J Clin Dermatol. 2009;10(6):351\u201364.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2430_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/00128071-200304020-00002","volume":"4","author":"JJ DiGiovanna","year":"2003","unstructured":"DiGiovanna JJ, Robinson-Bostom L. Ichthyosis: etiology, diagnosis, and management. Am J Clin Dermatol. 2003;4(2):81\u201395.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2430_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/00128071-200405010-00004","volume":"5","author":"T Shwayder","year":"2004","unstructured":"Shwayder T. Disorders of keratinization: diagnosis and management. Am J Clin Dermatol. 2004;5(1):17\u201329.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"2430_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jid.2018.08.027","volume":"139","author":"AS Paller","year":"2019","unstructured":"Paller AS. profiling immune expression to consider repurposing therapeutics for the ichthyoses. J Invest Dermatol. 2019;139(3):535\u201340.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2430_CR10","doi-asserted-by":"publisher","first-page":"adv00096","DOI":"10.2340\/00015555-3432","volume":"100","author":"J Fischer","year":"2020","unstructured":"Fischer J, Bourrat E. Genetics of inherited ichthyoses and related diseases. Acta Derm Venereol. 2020;100(7):adv00096.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"2430_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jaad.2009.04.028","volume":"62","author":"NF Fernandes","year":"2010","unstructured":"Fernandes NF, Janniger CK, Schwartz RA. X-linked ichthyosis: an oculocutaneous genodermatosis. J Am Acad Dermatol. 2010;62(3):480\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2430_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-017-0313-x","volume":"19","author":"A Vahlquist","year":"2018","unstructured":"Vahlquist A, Fischer J, Torma H. Inherited nonsyndromic ichthyoses: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2018;19(1):51\u201366.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"2430_CR13","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/ejhg.2017.137","volume":"25","author":"L Youssefian","year":"2017","unstructured":"Youssefian L, Vahidnezhad H, Saeidian AH, Sotoudeh S, Mahmoudi H, Daneshpazhooh M, et al. Autosomal recessive congenital ichthyosis: CERS3 mutations identified by a next generation sequencing panel targeting ichthyosis genes. Eur J Hum Genet. 2017;25(11):1282\u20135.","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"2430_CR14","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/exd.13813","volume":"28","author":"H Zhang","year":"2019","unstructured":"Zhang H, Ericsson M, Westrom S, Vahlquist A, Virtanen M, Torma H. Patients with congenital ichthyosis and TGM1 mutations overexpress other ARCI genes in the skin: part of a barrier repair response? Exp Dermatol. 2019;28(10):1164\u201371.","journal-title":"Exp Dermatol"},{"issue":"3","key":"2430_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbalip.2013.08.020","volume":"1841","author":"A Munoz-Garcia","year":"2014","unstructured":"Munoz-Garcia A, Thomas CP, Keeney DS, Zheng Y, Brash AR. The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier. Biochim Biophys Acta. 2014;1841(3):401\u20138.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2430_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jid.2017.11.008","volume":"138","author":"Y Honda","year":"2018","unstructured":"Honda Y, Kitamura T, Naganuma T, Abe T, Ohno Y, Sassa T, et al. Decreased skin barrier lipid acylceramide and differentiation-dependent gene expression in ichthyosis gene Nipal4-knockout mice. J Invest Dermatol. 2018;138(4):741\u20139.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2430_CR17","doi-asserted-by":"publisher","first-page":"e0170708","DOI":"10.1371\/journal.pone.0170708","volume":"12","author":"ML Casal","year":"2017","unstructured":"Casal ML, Wang P, Mauldin EA, Lin G, Henthorn PS. A defect in NIPAL4 Is associated with autosomal recessive congenital ichthyosis in american bulldogs. PLoS ONE. 2017;12(1):e0170708.","journal-title":"PLoS ONE"},{"issue":"6","key":"2430_CR18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bbalip.2018.09.010","volume":"1864","author":"T Hirabayashi","year":"2019","unstructured":"Hirabayashi T, Murakami M, Kihara A. The role of PNPLA1 in omega-O-acylceramide synthesis and skin barrier function. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(6):869\u201379.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"5","key":"2430_CR19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1086\/429844","volume":"76","author":"DP Kelsell","year":"2005","unstructured":"Kelsell DP, Norgett EE, Unsworth H, Teh MT, Cullup T, Mein CA, et al. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet. 2005;76(5):794\u2013803.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"2430_CR20","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1172\/JCI24834","volume":"115","author":"M Akiyama","year":"2005","unstructured":"Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. 2005;115(7):1777\u201384.","journal-title":"J Clin Invest"},{"issue":"4","key":"2430_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00439-009-0646-5","volume":"125","author":"MJ Arin","year":"2009","unstructured":"Arin MJ. The molecular basis of human keratin disorders. Hum Genet. 2009;125(4):355\u201373.","journal-title":"Hum Genet"},{"issue":"2","key":"2430_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1365-2133.2010.10096.x","volume":"164","author":"MJ Arin","year":"2011","unstructured":"Arin MJ, Oji V, Emmert S, Hausser I, Traupe H, Krieg T, et al. Expanding the keratin mutation database: novel and recurrent mutations and genotype-phenotype correlations in 28 patients with epidermolytic ichthyosis. Br J Dermatol. 2011;164(2):442\u20137.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2430_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/ced.13324","volume":"43","author":"D Vodo","year":"2018","unstructured":"Vodo D, Sarig O, Peled A, Samuelov L, Malchin N, Grafi-Cohen M, et al. Recessive epidermolytic ichthyosis results from loss of keratin 10 expression, regardless of the mutation location. Clin Exp Dermatol. 2018;43(2):187\u201390.","journal-title":"Clin Exp Dermatol"},{"issue":"6000","key":"2430_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1126\/science.1192280","volume":"330","author":"KA Choate","year":"2010","unstructured":"Choate KA, Lu Y, Zhou J, Choi M, Elias PM, Farhi A, et al. Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10. Science. 2010;330(6000):94\u20137.","journal-title":"Science"},{"issue":"4","key":"2430_CR25","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1172\/JCI64415","volume":"125","author":"KA Choate","year":"2015","unstructured":"Choate KA, Lu Y, Zhou J, Elias PM, Zaidi S, Paller AS, et al. Frequent somatic reversion of KRT1 mutations in ichthyosis with confetti. J Clin Invest. 2015;125(4):1703\u20137.","journal-title":"J Clin Invest"},{"issue":"10","key":"2430_CR26","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jid.2016.07.005","volume":"136","author":"YH Lim","year":"2016","unstructured":"Lim YH, Choate KA. Expanding the mutation spectrum of ichthyosis with confetti. J Invest Dermatol. 2016;136(10):1941\u20133.","journal-title":"J Invest Dermatol"},{"key":"2430_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13023-015-0336-4","volume":"10","author":"L Guerra","year":"2015","unstructured":"Guerra L, Diociaiuti A, El Hachem M, Castiglia D, Zambruno G. Ichthyosis with confetti: clinics, molecular genetics and management. Orphanet J Rare Dis. 2015;10:115.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"2430_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/21678707.2020.1857724","volume":"8","author":"EHA Petrova","year":"2020","unstructured":"Petrova EHA. Advances in understanding of Netherton syndrome and therapeutic implications. Expert Opin Orphan Drugs. 2020;8(11):455\u201387.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"5","key":"2430_CR29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjd.17820","volume":"181","author":"H Wiegmann","year":"2019","unstructured":"Wiegmann H, Valentin F, Tarinski T, Liebau E, Loser K, Traupe H, et al. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome. Br J Dermatol. 2019;181(5):999\u20131008.","journal-title":"Br J Dermatol"},{"issue":"9","key":"2430_CR30","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/j.jid.2021.01.029","volume":"141","author":"J Liddle","year":"2021","unstructured":"Liddle J, Beneton V, Benson M, Bingham R, Bouillot A, Boullay AB, et al. A potent and selective kallikrein-5 inhibitor delivers high pharmacological activity in skin from patients with Netherton syndrome. J Invest Dermatol. 2021;141(9):2272\u20139.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2430_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2006.08.006","volume":"90","author":"WB Rizzo","year":"2007","unstructured":"Rizzo WB. Sjogren\u2013Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab. 2007;90(1):1\u20139.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2430_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/21678707.2016.1154453","volume":"4","author":"WB Rizzo","year":"2016","unstructured":"Rizzo WB. Genetics and prospective therapeutic targets for Sjogren\u2013Larsson syndrome. Expert Opin Orphan Drugs. 2016;4(4):395\u2013406.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"13","key":"2430_CR33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/sj.gt.3302743","volume":"13","author":"S Haug","year":"2006","unstructured":"Haug S, Braun-Falco M. Restoration of fatty aldehyde dehydrogenase deficiency in Sjogren\u2013Larsson syndrome. Gene Ther. 2006;13(13):1021\u20136.","journal-title":"Gene Ther"},{"issue":"10","key":"2430_CR34","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/ng.2739","volume":"45","author":"L Samuelov","year":"2013","unstructured":"Samuelov L, Sarig O, Harmon RM, Rapaport D, Ishida-Yamamoto A, Isakov O, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet. 2013;45(10):1244\u20138.","journal-title":"Nat Genet"},{"issue":"5","key":"2430_CR35","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jaci.2015.05.002","volume":"136","author":"MA McAleer","year":"2015","unstructured":"McAleer MA, Pohler E, Smith FJ, Wilson NJ, Cole C, MacGowan S, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol. 2015;136(5):1268\u201376.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2430_CR36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/bjd.19546","volume":"184","author":"F Valentin","year":"2021","unstructured":"Valentin F, Wiegmann H, Tarinski T, Nikolenko H, Traupe H, Liebau E, et al. Development of a pathogenesis-based therapy for peeling skin syndrome type 1. Br J Dermatol. 2021;184(6):1123\u201331.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2430_CR37","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1086\/339986","volume":"70","author":"G Richard","year":"2002","unstructured":"Richard G, Rouan F, Willoughby CE, Brown N, Chung P, Ryynanen M, et al. Missense mutations in GJB2 encoding connexin-26 cause the ectodermal dysplasia keratitis\u2013ichthyosis\u2013deafness syndrome. Am J Hum Genet. 2002;70(5):1341\u20138.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2430_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1046\/j.1523-1747.2002.01735.x","volume":"118","author":"MA van Steensel","year":"2002","unstructured":"van Steensel MA, van Geel M, Nahuys M, Smitt JH, Steijlen PM. A novel connexin 26 mutation in a patient diagnosed with keratitis\u2013ichthyosis\u2013deafness syndrome. J Invest Dermatol. 2002;118(4):724\u20137.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2430_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1525-1470.1996.tb01414.x","volume":"13","author":"H Caceres-Rios","year":"1996","unstructured":"Caceres-Rios H, Tamayo-Sanchez L, Duran-Mckinster C, de la Luz OM, Ruiz-Maldonado R. Keratitis, ichthyosis, and deafness (KID syndrome): review of the literature and proposal of a new terminology. Pediatr Dermatol. 1996;13(2):105\u201313.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"2430_CR40","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ophtha.2004.07.034","volume":"112","author":"EM Messmer","year":"2005","unstructured":"Messmer EM, Kenyon KR, Rittinger O, Janecke AR, Kampik A. Ocular manifestations of keratitis\u2013ichthyosis\u2013deafness (KID) syndrome. Ophthalmology. 2005;112(2):e1-6.","journal-title":"Ophthalmology"},{"issue":"3","key":"2430_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1346-8138.13284","volume":"43","author":"K Yoneda","year":"2016","unstructured":"Yoneda K. Inherited ichthyosis: syndromic forms. J Dermatol. 2016;43(3):252\u201363.","journal-title":"J Dermatol"},{"issue":"3","key":"2430_CR42","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ajmg.a.38619","volume":"176","author":"C Bergqvist","year":"2018","unstructured":"Bergqvist C, Abdallah B, Hasbani DJ, Abbas O, Kibbi AG, Hamie L, et al. CHILD syndrome: a modified pathogenesis-targeted therapeutic approach. Am J Med Genet A. 2018;176(3):733\u20138.","journal-title":"Am J Med Genet A"},{"issue":"9","key":"2430_CR43","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/jid.2011.124","volume":"131","author":"L Fontao","year":"2011","unstructured":"Fontao L, Laffitte E, Briot A, Kaya G, Roux-Lombard P, Fraitag S, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol. 2011;131(9):1947\u201350.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2430_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jdcr.2017.07.019","volume":"3","author":"A Roda","year":"2017","unstructured":"Roda A, Mendonca-Sanches M, Travassos AR, Soares-de-Almeida L, Metze D. Infliximab therapy for Netherton syndrome: a case report. JAAD Case Rep. 2017;3(6):550\u20132.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"2430_CR45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.16882","volume":"180","author":"J Mazereeuw-Hautier","year":"2019","unstructured":"Mazereeuw-Hautier J, Hernandez-Martin A, O\u2019Toole EA, Bygum A, Amaro C, Aldwin M, et al. Management of congenital ichthyoses: European guidelines of care, part two. Br J Dermatol. 2019;180(3):484\u201395.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2430_CR46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jaci.2016.07.019","volume":"139","author":"AS Paller","year":"2017","unstructured":"Paller AS, Renert-Yuval Y, Suprun M, Esaki H, Oliva M, Huynh TN, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139(1):152\u201365.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2430_CR47","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.jid.2018.03.1523","volume":"138","author":"T Czarnowicki","year":"2018","unstructured":"Czarnowicki T, He H, Leonard A, Malik K, Magidi S, Rangel S, et al. The major orphan forms of ichthyosis are characterized by systemic T-cell activation and Th-17\/Tc-17\/Th-22\/Tc-22 polarization in blood. J Invest Dermatol. 2018;138(10):2157\u201367.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2430_CR48","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jaci.2018.03.021","volume":"143","author":"K Malik","year":"2019","unstructured":"Malik K, He H, Huynh TN, Tran G, Mueller K, Doytcheva K, et al. Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol. 2019;143(2):604\u201318.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"2430_CR49","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1001\/jamadermatol.2020.1018","volume":"156","author":"AS Paller","year":"2020","unstructured":"Paller AS. Pathogenesis-based therapy with repurposed biologics for monogenic inflammatory skin disorders. JAMA Dermatol. 2020;156(8):839\u201341.","journal-title":"JAMA Dermatol"},{"issue":"Suppl 2","key":"2430_CR50","doi-asserted-by":"publisher","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","volume":"72","author":"DD Patel","year":"2013","unstructured":"Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii116-23.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2430_CR51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamadermatol.2020.1019","volume":"156","author":"I Luchsinger","year":"2020","unstructured":"Luchsinger I, Knopfel N, Theiler M, des Bonnet Claustres M, Barbieux C, Schwieger-Briel A, et al. Secukinumab therapy for Netherton syndrome. JAMA Dermatol. 2020;156(8):907\u201311.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2430_CR52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jdcr.2020.04.025","volume":"6","author":"SK Blanchard","year":"2020","unstructured":"Blanchard SK, Prose NS. Successful use of secukinumab in Netherton syndrome. JAAD Case Rep. 2020;6(6):577\u20138.","journal-title":"JAAD Case Rep"},{"issue":"5","key":"2430_CR53","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bjd.16497","volume":"178","author":"C Paul","year":"2018","unstructured":"Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178(5):1003\u20135.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2430_CR54","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jaad.2020.07.054","volume":"84","author":"C Barbieux","year":"2021","unstructured":"Barbieux C, Des Claustres MB, De la Brassinne M, Bagot M, Bourrat E, Hovnanian A. Duality of Netherton syndrome manifestations and response to ixekizumab. J Am Acad Dermatol. 2021;84(5):1476\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"2430_CR55","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2165\/11207530-000000000-00000","volume":"71","author":"JD Croxtall","year":"2011","unstructured":"Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs. 2011;71(13):1733\u201353.","journal-title":"Drugs"},{"issue":"1","key":"2430_CR56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/bjd.18892","volume":"183","author":"S Volc","year":"2020","unstructured":"Volc S, Maier L, Gritsch A, Aichelburg MC, Volc-Platzer B. Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl. Br J Dermatol. 2020;183(1):165\u20137.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2430_CR57","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2133.2010.09855.x","volume":"163","author":"J Wohlrab","year":"2010","unstructured":"Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol. 2010;163(3):655\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2430_CR58","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bjd.12952","volume":"171","author":"O Eytan","year":"2014","unstructured":"Eytan O, Sarig O, Sprecher E, van Steensel MA. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol. 2014;171(2):420\u20132.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2430_CR59","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjd.15462","volume":"178","author":"SM Lwin","year":"2018","unstructured":"Lwin SM, Hsu CK, Liu L, Huang HY, Levell NJ, McGrath JA. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14. Br J Dermatol. 2018;178(4):969\u201372.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2430_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/jamadermatol.2019.4608","volume":"156","author":"AB Steuer","year":"2020","unstructured":"Steuer AB, Cohen DE. Treatment of Netherton syndrome with dupilumab. JAMA Dermatol. 2020;156(3):350\u20131.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"2430_CR61","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/ced.14317","volume":"45","author":"TH Andreasen","year":"2020","unstructured":"Andreasen TH, Karstensen HG, Duno M, Lei U, Zachariae C, Thyssen JP. Successful treatment with dupilumab of an adult with Netherton syndrome. Clin Exp Dermatol. 2020;45(7):915\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2430_CR62","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/1346-8138.16253","volume":"49","author":"J Wang","year":"2022","unstructured":"Wang J, Yu L, Zhang S, Wang C, Li Z, Li M, et al. Successful treatment of Netherton syndrome with dupilumab: a case report and review of the literature. J Dermatol. 2022;49(1):165\u20137.","journal-title":"J Dermatol"},{"issue":"2","key":"2430_CR63","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/jdv.16883","volume":"35","author":"K Sussmuth","year":"2021","unstructured":"Sussmuth K, Traupe H, Loser K, Stander S, Kessel C, Wittkowski H, et al. Response to dupilumab in two children with Netherton syndrome: improvement of pruritus and scaling. J Eur Acad Dermatol Venereol. 2021;35(2):e152\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2430_CR64","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jdermsci.2021.03.003","volume":"102","author":"C Murase","year":"2021","unstructured":"Murase C, Takeichi T, Taki T, Yoshikawa T, Suzuki A, Ogi T, et al. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome. J Dermatol Sci. 2021;102(2):126\u20139.","journal-title":"J Dermatol Sci"},{"issue":"6","key":"2430_CR65","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/pde.14362","volume":"37","author":"M Aktas","year":"2020","unstructured":"Aktas M, Salman A, Apti Sengun O, Comert Ozer E, Hosgoren Tekin S, Akin Cakici O, et al. Netherton syndrome: temporary response to dupilumab. Pediatr Dermatol. 2020;37(6):1210\u20131.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2430_CR66","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/pde.13995","volume":"36","author":"C Poulton","year":"2019","unstructured":"Poulton C, Gration D, Murray K, Baynam G, Halbert A. Autosomal recessive congenital ichthyosis due to homozygous variants in NIPAL4 with a dramatic response to ustekinumab. Pediatr Dermatol. 2019;36(6):1002\u20133.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"2430_CR67","first-page":"70","volume":"17","author":"D Haiges","year":"2019","unstructured":"Haiges D, Fischer J, Horer S, Has C, Schempp CM. Biologic therapy targeting IL-17 ameliorates a case of congenital ichthyosiform cornification disorder. J Dtsch Dermatol Ges. 2019;17(1):70\u20132.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"22","key":"2430_CR68","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1056\/NEJMc1908531","volume":"381","author":"A Hernandez-Martin","year":"2019","unstructured":"Hernandez-Martin A, Kennedy-Batalla R, Canedo E, Bernaldo-de-Quiros E, Carazo-Gallego B, Vera A, et al. Imbalance in T-Helper 17 cells and targeted therapy in an infant with SAM-like syndrome. N Engl J Med. 2019;381(22):2176\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"2430_CR69","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jaad.2017.10.026","volume":"78","author":"AS Paller","year":"2018","unstructured":"Paller AS, Czarnowicki T, Renert-Yuval Y, Holland K, Huynh T, Sadlier M, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: immunophenotyping and response to ustekinumab. J Am Acad Dermatol. 2018;78(3):498-505 e2.","journal-title":"J Am Acad Dermatol"},{"key":"2430_CR70","doi-asserted-by":"crossref","unstructured":"Lefferdink R, Rangel SM, Chima M, Ibler E, Pavel AB, Kim H, et al. Secukinumab responses vary across the spectrum of congenital ichthyosis in adults. Arch Dermatol Res. 2022.","DOI":"10.1007\/s00403-022-02325-3"},{"issue":"12","key":"2430_CR71","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.bmcl.2019.04.022","volume":"29","author":"AL Walker","year":"2019","unstructured":"Walker AL, Bingham RP, Edgar EV, Ferrie A, Holmes DS, Liddle J, et al. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome. Bioorg Med Chem Lett. 2019;29(12):1454\u20138.","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"2430_CR72","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ddr.21263","volume":"76","author":"T Torres","year":"2015","unstructured":"Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res. 2015;76(5):215\u201327.","journal-title":"Drug Dev Res"},{"issue":"4","key":"2430_CR73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14712598.2019.1573422","volume":"19","author":"R Li","year":"2019","unstructured":"Li R, Hadi S, Guttman-Yassky E. Current and emerging biologic and small molecule therapies for atopic dermatitis. Expert Opin Biol Ther. 2019;19(4):367\u201380.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"2430_CR74","doi-asserted-by":"publisher","first-page":"e1005389","DOI":"10.1371\/journal.pgen.1005389","volume":"11","author":"L Furio","year":"2015","unstructured":"Furio L, Pampalakis G, Michael IP, Nagy A, Sotiropoulou G, Hovnanian A. KLK5 inactivation reverses cutaneous hallmarks of netherton syndrome. PLoS Genet. 2015;11(9):e1005389.","journal-title":"PLoS Genet"},{"issue":"7","key":"2430_CR75","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/exd.12451","volume":"23","author":"S Wang","year":"2014","unstructured":"Wang S, Olt S, Schoefmann N, Stuetz A, Winiski A, Wolff-Winiski B. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7. Exp Dermatol. 2014;23(7):524\u20136.","journal-title":"Exp Dermatol"},{"issue":"1","key":"2430_CR76","doi-asserted-by":"publisher","first-page":"e1006566","DOI":"10.1371\/journal.pgen.1006566","volume":"13","author":"P Kasparek","year":"2017","unstructured":"Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, et al. KLK5 and KLK7 ablation fully rescues lethality of Netherton syndrome-like phenotype. PLoS Genet. 2017;13(1):e1006566.","journal-title":"PLoS Genet"},{"issue":"1","key":"2430_CR77","doi-asserted-by":"publisher","first-page":"e0210842","DOI":"10.1371\/journal.pone.0210842","volume":"14","author":"X Chen","year":"2019","unstructured":"Chen X, Riley BT, de Veer SJ, Hoke DE, Van Haeften J, Leahy D, et al. Potent, multi-target serine protease inhibition achieved by a simplified beta-sheet motif. PLoS ONE. 2019;14(1):e0210842.","journal-title":"PLoS ONE"},{"issue":"3","key":"2430_CR78","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/archderm.142.3.396","volume":"142","author":"J Mazereeuw-Hautier","year":"2006","unstructured":"Mazereeuw-Hautier J, Cope J, Ong C, Green A, Hovnanian A, Harper JI. Topical recombinant alpha1-antitrypsin: a potential treatment for Netherton syndrome? Arch Dermatol. 2006;142(3):396\u20138.","journal-title":"Arch Dermatol"},{"key":"2430_CR79","unstructured":"Chateau M. A phase I\/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-in-human (FIH) Proof of Concept (PoC) study to evaluate the safety and efficacy of topically applied SXR1096 cream in patients with Netherton syndrome (NS): Sixera Pharma; 2021. http:\/\/sixerapharma.com\/2021\/12\/07\/15398\/. Accessed 9 Jand 2022."},{"key":"2430_CR80","unstructured":"Inc AT. Aldeyra therapeutics announces first patient enrolled in Sj\u00f6gren\u2013Larsson syndrome pivotal phase 3 Clinical trial 2018. https:\/\/ir.aldeyra.com\/news-releases\/news-release-details\/aldeyra-therapeutics-announces-first-patient-enrolled-sjogren-0. Accessed 15 Feb 2022."},{"issue":"6","key":"2430_CR81","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/MOP.0b013e32834c20d9","volume":"23","author":"RH Lachmann","year":"2011","unstructured":"Lachmann RH. Enzyme replacement therapy for lysosomal storage diseases. Curr Opin Pediatr. 2011;23(6):588\u201393.","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"2430_CR82","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ajhg.2013.08.003","volume":"93","author":"K Aufenvenne","year":"2013","unstructured":"Aufenvenne K, Larcher F, Hausser I, Duarte B, Oji V, Nikolenko H, et al. Topical enzyme-replacement therapy restores transglutaminase 1 activity and corrects architecture of transglutaminase-1-deficient skin grafts. Am J Hum Genet. 2013;93(4):620\u201330.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"2430_CR83","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/jid.2009.57","volume":"129","author":"J Fischer","year":"2009","unstructured":"Fischer J. Autosomal recessive congenital ichthyosis. J Invest Dermatol. 2009;129(6):1319\u201321.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2430_CR84","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jid.2018.11.002","volume":"139","author":"R Plank","year":"2019","unstructured":"Plank R, Yealland G, Miceli E, Lima Cunha D, Graff P, Thomforde S, et al. Transglutaminase 1 replacement therapy successfully mitigates the autosomal recessive congenital ichthyosis phenotype in full-thickness skin disease equivalents. J Invest Dermatol. 2019;139(5):1191\u20135.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2430_CR85","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jid.2016.08.036","volume":"137","author":"S Grond","year":"2017","unstructured":"Grond S, Eichmann TO, Dubrac S, Kolb D, Schmuth M, Fischer J, et al. PNPLA1 deficiency in mice and humans leads to a defect in the synthesis of omega-O-acylceramides. J Invest Dermatol. 2017;137(2):394\u2013402.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2430_CR86","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.ajpath.2018.02.008","volume":"188","author":"EA Mauldin","year":"2018","unstructured":"Mauldin EA, Crumrine D, Casal ML, Jeong S, Opalka L, Vavrova K, et al. Cellular and metabolic basis for the ichthyotic phenotype in NIPAL4 (Ichthyin)-deficient canines. Am J Pathol. 2018;188(6):1419\u201329.","journal-title":"Am J Pathol"},{"issue":"11","key":"2430_CR87","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/jid.2011.189","volume":"131","author":"AS Paller","year":"2011","unstructured":"Paller AS, van Steensel MA, Rodriguez-Martin M, Sorrell J, Heath C, Crumrine D, et al. Pathogenesis-based therapy reverses cutaneous abnormalities in an inherited disorder of distal cholesterol metabolism. J Invest Dermatol. 2011;131(11):2242\u20138.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2430_CR88","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1590\/abd1806-4841.20198789","volume":"94","author":"KR Sandoval","year":"2019","unstructured":"Sandoval KR, Machado MCR, Oliveira ZNP, Nico MMS. CHILD syndrome: successful treatment of skin lesions with topical lovastatin and cholesterol lotion. An Bras Dermatol. 2019;94(3):341\u20133.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"2430_CR89","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/jdv.15838","volume":"34","author":"X Yu","year":"2020","unstructured":"Yu X, Chen L, Yang Z, Gu Y, Zheng W, Wu Z, et al. An excellent response to topical therapy of four congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome patients with an increased concentration of simvastatin ointment. J Eur Acad Dermatol Venereol. 2020;34(1):e8\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2430_CR90","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/pde.14865","volume":"39","author":"P Kallis","year":"2022","unstructured":"Kallis P, Bisbee E, Garganta C, Schoch JJ. Rapid improvement of skin lesions in CHILD syndrome with topical 5% simvastatin ointment. Pediatr Dermatol. 2022;39(1):151\u20132.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2430_CR91","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jdcr.2017.11.019","volume":"4","author":"SM Bajawi","year":"2018","unstructured":"Bajawi SM, Jafarri SA, Buraik MA, Al Attas KM, Hannani HY. Pathogenesis-based therapy: cutaneous abnormalities of CHILD syndrome successfully treated with topical simvastatin monotherapy. JAAD Case Rep. 2018;4(3):232\u20134.","journal-title":"JAAD Case Rep"},{"issue":"12","key":"2430_CR92","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nm1504","volume":"12","author":"F Mavilio","year":"2006","unstructured":"Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12(12):1397\u2013402.","journal-title":"Nat Med"},{"issue":"7680","key":"2430_CR93","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","volume":"551","author":"T Hirsch","year":"2017","unstructured":"Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551(7680):327\u201332.","journal-title":"Nature"},{"issue":"8","key":"2430_CR94","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.jid.2019.04.001","volume":"139","author":"G Bilousova","year":"2019","unstructured":"Bilousova G. Gene therapy for skin fragility diseases: the new generation. J Invest Dermatol. 2019;139(8):1634\u20137.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2430_CR95","doi-asserted-by":"publisher","first-page":"a015149","DOI":"10.1101\/cshperspect.a015149","volume":"4","author":"E Gorell","year":"2014","unstructured":"Gorell E, Nguyen N, Lane A, Siprashvili Z. Gene therapy for skin diseases. Cold Spring Harb Perspect Med. 2014;4(4):a015149.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"2430_CR96","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.3390\/ijms23052506","volume":"23","author":"DS Chulpanova","year":"2022","unstructured":"Chulpanova DS, Shaimardanova AA, Ponomarev AS, Elsheikh S, Rizvanov AA, Solovyeva VV. Current strategies for the gene therapy of autosomal recessive congenital ichthyosis and other types of inherited ichthyosis. Int J Mol Sci. 2022;23(5):2506.","journal-title":"Int J Mol Sci"},{"issue":"7\u20138","key":"2430_CR97","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00335-017-9688-5","volume":"28","author":"E Danner","year":"2017","unstructured":"Danner E, Bashir S, Yumlu S, Wurst W, Wefers B, Kuhn R. Control of gene editing by manipulation of DNA repair mechanisms. Mamm Genome. 2017;28(7\u20138):262\u201374.","journal-title":"Mamm Genome"},{"issue":"12","key":"2430_CR98","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","volume":"19","author":"EM Porto","year":"2020","unstructured":"Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov. 2020;19(12):839\u201359.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2430_CR99","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/hmg\/6.6.927","volume":"6","author":"RA Freiberg","year":"1997","unstructured":"Freiberg RA, Choate KA, Deng H, Alperin ES, Shapiro LJ, Khavari PA. A model of corrective gene transfer in X-linked ichthyosis. Hum Mol Genet. 1997;6(6):927\u201333.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"2430_CR100","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00403-005-0556-x","volume":"296","author":"S Haug","year":"2005","unstructured":"Haug S, Braun-Falco M. Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjogren\u2013Larsson syndrome. Arch Dermatol Res. 2005;296(12):568\u201372.","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"2430_CR101","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.jid.2019.03.1146","volume":"139","author":"OP March","year":"2019","unstructured":"March OP, Lettner T, Klausegger A, Ablinger M, Kocher T, Hainzl S, et al. Gene editing-mediated disruption of epidermolytic ichthyosis-associated KRT10 alleles restores filament stability in keratinocytes. J Invest Dermatol. 2019;139(8):1699-710 e6.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2430_CR102","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm1196-1263","volume":"2","author":"KA Choate","year":"1996","unstructured":"Choate KA, Medalie DA, Morgan JR, Khavari PA. Corrective gene transfer in the human skin disorder lamellar ichthyosis. Nat Med. 1996;2(11):1263\u20137.","journal-title":"Nat Med"},{"issue":"4","key":"2430_CR103","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jid.2020.07.035","volume":"141","author":"JC Freedman","year":"2021","unstructured":"Freedman JC, Parry TJ, Zhang P, Majumdar A, Krishnan S, Regula LK, et al. Preclinical evaluation of a modified herpes simplex virus type 1 vector encoding human TGM1 for the treatment of autosomal recessive congenital ichthyosis. J Invest Dermatol. 2021;141(4):874-82 e6.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2430_CR104","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","volume":"28","author":"I Gurevich","year":"2022","unstructured":"Gurevich I, Agarwal P, Zhang P, Dolorito JA, Oliver S, Liu H, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022;28(4):780\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"2430_CR105","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ymthe.2021.05.007","volume":"30","author":"L Dang","year":"2022","unstructured":"Dang L, Zhou X, Zhong X, Yu W, Huang S, Liu H, et al. Correction of the pathogenic mutation in TGM1 gene by adenine base editing in mutant embryos. Mol Ther. 2022;30(1):175\u201383.","journal-title":"Mol Ther"},{"issue":"5","key":"2430_CR106","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jid.2019.09.022","volume":"140","author":"MY Lee","year":"2020","unstructured":"Lee MY, Wang HZ, White TW, Brooks T, Pittman A, Halai H, et al. Allele-specific small interfering RNA corrects aberrant cellular phenotype in keratitis\u2013ichthyosis\u2013deafness syndrome keratinocytes. J Invest Dermatol. 2020;140(5):1035\u201344.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"2430_CR107","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1089\/hum.2019.049","volume":"30","author":"WL Di","year":"2019","unstructured":"Di WL, Lwin SM, Petrova A, Bernadis C, Syed F, Farzaneh F, et al. Generation and clinical application of gene-modified autologous epidermal sheets in Netherton syndrome: lessons learned from a phase 1 trial. Hum Gene Ther. 2019;30(9):1067\u201378.","journal-title":"Hum Gene Ther"},{"issue":"76","key":"2430_CR108","first-page":"167","volume":"14","author":"AM Pasmooij","year":"2012","unstructured":"Pasmooij AM, Jonkman MF, Uitto J. Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy. Discov Med. 2012;14(76):167\u201379.","journal-title":"Discov Med"},{"issue":"1","key":"2430_CR109","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaad.2013.08.052","volume":"70","author":"A Gostynski","year":"2014","unstructured":"Gostynski A, Pasmooij AM, Jonkman MF. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa. J Am Acad Dermatol. 2014;70(1):98\u2013101.","journal-title":"J Am Acad Dermatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02430-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02430-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02430-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T14:08:40Z","timestamp":1657894120000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02430-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2430"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02430-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AG: speakers fee by Abbvie for a presentation about genodermatosis on a Dutch dermatology congress, including data about treatment of ichthyosis by IL-17 inhibitors; stocks AstraZeneca, Abott Laboratories, Abbvie, GSK, Incyte Corp, Krystal Biotech Inc, Sanofi, Johnson and Johnson, Novartis, Pfizer, UCB; Novartis is providing secukinumab free of charge for four patients with ichthyosis treated in my centre. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}